181 results
Page 2 of 10
8-K
zquyelb u5re7s1
10 Jan 22
Results of Operations and Financial Condition
7:04am
8-K
1ljyg8mprm6
22 Nov 21
Entry into a Material Definitive Agreement
7:03am
424B5
btzcofxejtmif
9 Aug 21
Prospectus supplement for primary offering
4:03pm
8-K
EX-99.1
7s6q vuj090x
5 Aug 21
BioCryst Reports Second Quarter 2021 Financial Results and Upcoming Key Milestones
7:06am
8-K
zm7 0i4sz4f89yf
12 May 21
BioCryst Receives UK Approval of ORLADEYO™ (berotralstat), First Oral, Once-daily Therapy to Prevent Attacks in Hereditary Angioedema Patients
9:45am
8-K
EX-99.1
09bwhhx0wn24 a78b6
12 May 21
BioCryst Receives UK Approval of ORLADEYO™ (berotralstat), First Oral, Once-daily Therapy to Prevent Attacks in Hereditary Angioedema Patients
9:45am
8-K
EX-99.1
93zi6m0y
6 May 21
BioCryst Reports First Quarter 2021 Financial Results and Upcoming Key Milestones
7:09am
8-K
EX-99.1
gq6 bolnhy
30 Apr 21
Regulation FD Disclosure
10:57am
8-K
5an32l4q0tgaj1zty
2 Mar 21
Regulation FD Disclosure
7:07am
8-K
EX-99.1
0kte4127nqau2t
2 Mar 21
Regulation FD Disclosure
7:07am
8-K
EX-99.1
f0devjny
25 Feb 21
Regulation FD Disclosure
4:40pm
8-K
EX-99.1
9w9ldln
25 Feb 21
BioCryst Reports Fourth Quarter and Full Year 2020 Financial Results and Upcoming Key Milestones
7:05am
8-K
EX-99.1
0akt1sjorzrdmw91e
7 Dec 20
BioCryst Announces $325 Million of Funding from Royalty Pharma and Athyrium Capital Management
9:34am
8-K
EX-99.1
aqj60
4 Dec 20
BioCryst Announces FDA Approval of ORLADEYO™ (berotralstat), First Oral, Once-daily Therapy to Prevent Attacks in Hereditary Angioedema Patients
12:00am